NEW YORK (GenomeWeb) – After launching its business with a focus on early cancer detection cancer, CellMax Life has now also begun offering germline DNA testing for detection of hereditary cancer risk mutations.

The company believes the new assay, called the CellMax-DNA Genetic Cancer Risk Test, will complement its planned slate of liquid biopsy assays for early cancer detection, the first of which it launched in Taiwan this summer.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.